+44 (0) 1223 737941 enquiries@cn-bio.com
  • Events
  • News
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
  • Events
  • News
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
CN Bio
  • Home
  • CN Bio
    • The Company
    • Management Team
    • Careers
  • Organ-On-Chip
    • About Organ-On-Chip
    • Liver-On-Chip
    • Barrier Models
    • 3D Cell Culture
    • Toxicology
    • Drug Metabolism
    • Disease Modelling
  • Products & Services
    • PhysioMimix™ OOC
      • Product Information
      • Consumables
      • T12
      • LC12
    • Human Cell Referral
    • NASH Fee-For-Service
  • Resources
    • Scientific Publications
    • Brochures
    • Videos
  • Contact
Select Page

CN Bio and Cambridge University identify novel regulatory pathway driving NASH

by CN Bio. | Jun 9, 2020 | Uncategorised

Paper published in Nature Metabolism demonstrates novel pathway regulating the underlying mechanism of liver fibrosis  Research harnesses CN Bio’s liver-on-chip NASH disease model, to advance development of potential new medicines for liver fibrosis  CN Bio, a...

Recent Posts

  • CN Bio and Cambridge University identify novel regulatory pathway driving NASH 9th June 2020
  • CN Bio Innovations raises $9 million USD (c. £6.9 million GBP) 2nd March 2020
  • NASH Drug Discovery Service Launched at AASLD 11th November 2019

Categories

  • Business
  • Media Coverage
  • Press releases
  • Uncategorised
Website built and designed by Website Energizers LTD | © 2020 CN Bio Innovations | Registered No. 06517359 | VAT No. 978184563 | Privacy Policy | Terms | Sitemap
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok